The real-world evidence significantly strengthens NRx's NDA filing for NRX-100, especially with regulatory tailwinds from the White House and Congress. Monitor for FDA acceptance of the NDA and any Type C meeting outcomes. The stock has historically shown strong positive drift on catalyst news (avg T+20 +35% on prior bullish calls).
Price Chart
Executive Summary
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.
Key Facts
- IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
- Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
- 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
- NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.
- White House Executive Order and House Appropriations language support use of real-world evidence for depression drug approvals.
- NRx has Fast Track Designation for NRX-100 in suicidal depression and Breakthrough Therapy Designation for NRX-101 in suicidal bipolar depression.
Financial Impact
No financial figures disclosed; potential market opportunity for NRX-100 in suicidal depression (large unmet need) but no revenue or deal value provided.
Risk Factors
- Study limitations: non-randomized design, potential unmeasured confounding variables.
- FDA may still require randomized controlled trials for full approval, despite real-world evidence support.
- NRx is a clinical-stage biopharma with no approved products and no disclosed revenue.
- Competition from existing esketamine (Spravato) and other NMDA-targeting therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.89 (−13.58%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.89 (−17.05%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.89 (−15.60%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.89 (−15.60%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.89 (−19.13%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.89 (−35.38%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.89 (−25.77%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.89 (−30.07%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.89 (+30.07%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.89 (+28.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access